Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01672229 · ClinicalTrials.gov registry record · Phase 1
Bortezomib in Patients With Chronic Graft Versus Host Disease
A Phase 1 study, sponsored by Mehrdad Abedi, MD.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT01672229 is a Phase 1 study that has completed, run by Mehrdad Abedi, MD. The registered enrollment target is 16 participants.
The verdict
NCT01672229, a Phase 1 study, has completed, sponsored by Mehrdad Abedi, MD.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
This study will investigate whether bortezomib can control the immune system and can be used to treat GVHD. Bortezomib has been used with not too many serious side effects in patients with multiple myeloma who will undergo transplant and also for acute graft versus host disease.
Interventions
- DRUG Bortezomib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2012-07 |
| Est. Completion | 2018-04-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01672229
The ClinicalTrials.gov registry entry for NCT01672229 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mehrdad Abedi, MD, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Bortezomib is the first listed.
NCT01672229 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01672229 about?
NCT01672229 is a clinical study titled "Bortezomib in Patients With Chronic Graft Versus Host Disease". This study will investigate whether bortezomib can control the immune system and can be used to treat GVHD. Bortezomib has been used with not too many serious side effects in patients with multiple myeloma who will undergo transplant and also for acute graft versus host disease.
What is the current status of trial NCT01672229?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2012-07. Estimated completion is 2018-04-09.
What interventions are being tested in trial NCT01672229?
The interventions under investigation include: Bortezomib (DRUG).
Who is sponsoring clinical trial NCT01672229?
This trial is sponsored by Mehrdad Abedi, MD, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.